July 6, 2020 -- CSL Behring has enrolled the first patient in its phase clinical II study to assess the safety and efficacy of CSL312 (garadacimab, factor XIIa-inhibitory monoclonal antibody) to treat respiratory distress associated with COVID-19.
The multicenter, double-blind, placebo-controlled study will enroll approximately 124 adult patients with COVID-19. CSL312 will be administered intravenously in combination with standard-of-care treatments.
CSL312 inhibits the plasma protein, Factor XIIa, to prevent the molecular cascade leading to edema formation. It is also under clinical development as a once-monthly subcutaneous prophylactic treatment for attacks related to hereditary angioedema.
In addition to the study of CSL312, the company is also:
- Working with the Coalition for Epidemic Preparedness Innovations (CEPI), and the University of Queensland on a COVID-19 vaccine
- Working with the CoVIg-19 Plasma Alliance to develop anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin treatment
- Developing an anti-SARS-CoV-2 plasma product for the Australian market
- Partnering with SAB Biotherapeutics to develop a novel immunotherapy targeting COVID-19
Copyright © 2020 scienceboard.net